Jonsson Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jonsson Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count).
Jonsson Comprehensive Cancer Center: 321 sponsored US clinical trials, 61 recruiting.
Jonsson Comprehensive Cancer Center sponsors 321 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 164 completed. 13 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Carcinoma, with 10 trials.
Top-decile sponsor footprint
Jonsson Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
164 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
321 total, page 4 of 7
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
NCT03128619
MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer
NCT06090630
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
NCT03240861
Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors
NCT03319342
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
NCT02775292
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
NCT02880020
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
NCT03368547
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
NCT02940262
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
NCT02879994
Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer
NCT02681601
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT02830165
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
NCT02928510
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
NCT02925351
Focal Laser Ablation of Prostate Tissue
NCT02357121
Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma
NCT02672033
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
NCT02902757
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
NCT01345136
18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
NCT02888301
Project Connect Online: An Internet-based Intervention for Women With Breast Cancer
NCT02866994
MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer
NCT02683200
Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer
NCT02425228
Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
NCT02575027
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
NCT02015559
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
NCT02336763
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer
NCT02224911
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
NCT02070406
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT02049593
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
NCT01784640
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
NCT01912820
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
NCT02048020
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
NCT01873248
Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer
NCT02092948
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
NCT01783756
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
NCT01826877
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
NCT01591577
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
NCT01664754
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
NCT01813877
Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors
NCT01627366
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
NCT01624285
Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors
NCT01540955
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
NCT01635283
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
NCT01536743
Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
NCT01532362
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00998010
Predictors of Patient Attitudes and Barriers to Skin Cancer Screening
NCT02235116
A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors
NCT01558258
Dendritic Cell Vaccine for Patients With Brain Tumors
NCT01204684
Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy
NCT02310594
Cellular Immunotherapy Study for Brain Cancer
NCT01144247
Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention
NCT01351220
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 100 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Jonsson Comprehensive Cancer Center pipeline
61 recruiting of 321 indexed (19% open); 164 completed (51%).
Phase mix: 13 late (III/IV) vs 206 early (I/II) (early-phase heavy).
Top condition: Prostate Carcinoma (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jonsson Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 321 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 321 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Allergan · 314 trials · 0% recruiting
- Genentech · 332 trials · 7% recruiting
Sponsors near 19% open enrollment (± trial volume)
- MemorialCare Health System · 19% recruiting · 21 trials
- University of North Texas Health Science Center · 19% recruiting · 21 trials
- University of Wisconsin, Milwaukee · 19% recruiting · 21 trials
- Verastem · 19% recruiting · 21 trials
Related
What to do with this Jonsson Comprehensive Cancer Center page
321 registered trials is a research-attention snapshot, not an endorsement of Jonsson Comprehensive Cancer Center or any single study.
- 61 of Jonsson Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Carcinoma is the condition Jonsson Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jonsson Comprehensive Cancer Center pipeline card: 321 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.